patients received a NMSCT for acute and chronic leukemia, myeloma and MDS in 33 centres of the EBMT. Complete data are available for 73 patients with AML, 39 ALL, 58 CML, 14 CLL, 57 MDS, 54 myeloma, 2 MPS, and 5 others. The median age was 50.9 years (range 3-68), and 170 were males. 79 were considered good risk at the time of transplant i.e. CML CP1, AML CR1-2, ALL CR1, myeloma CR1-PR1, CLL CR1/PR1, and MDS RA/RAS. 239 received grafts from HLA identical siblings, 38 from matched unrelated donors, and 18 from mismatched family or unrelated donors. 208 patients were transplanted with PBSC, 67 with BM, and 3 received both PBSC and BM. The majority of patients (268) received fludarabine based conditioning, 129 with busulphan, and 85 with melphalan. Cyclosporin was used in 281 transplants, and serotherapy in 183 patients (ATG/ALG 148, Campath 35). 20 patients did not engraft (6.6%). The median times to neutrophil ( Ͼ 0.5 x 10 exp9/L) and platelet ( Ͼ 50 x 10 exp9/L) engraftment were 15 (0-76) and 17 (0-84) days respectively. The TRM at 6 months was 32%. Acute GVHD grade II-IV occured in 25.4% of patients at risk (267). Data relating to chimerism were available from 228 patients. Their best response was Ͼ95% donor chimerism in 76.3 %. DLI was used in 55 patients, the vast majority because of disease persistence/relapse. The actuarial survivals (OS) for the whole cohort at 6, 12, and 24 months were 65%, 53 %, and 44 % respectively. OS at one year for CML, CLL, AML, ALL, MDS and myeloma, were 73%, 89%, 41%, 17%, 67%, and 52% respectively. The one year OS for the good (median age 54 years) and poor (median age 50 years) risk patients as defined above were 68% and 47% (p=0.0003). However the outcome for patients with ALL was particularly poor. If ALL CR1 was excluded from the good risk group then the OS, TRM, and relapse rate rate at one year were 78%, 14%, and 9%, compared with 47%, 47%, and 20% for the poor risk group. In conclusion, NMSCT is a useful alternative to conventional SCT in this cohort of older patients. The TRM for patients with good risk disease (excluding ALL CR1) is acceptable and overall survival at one year is promising. Further follow-up will be required to identify the long term benefit of these procedures with respect to disease free survival. Patients with ALL do not appear to benefit from NMSCT at any stage of their disease. The use of donor lymphocyte infusions was infrequent, but may be required to optimise the graft versus tumor effect. Patients over the age of 55 and patients with comorbidity have traditionally been excluded from allogeneic stem cell transplantation (SCT) because of the high transplant -related mortality (TRM) in this group of patients.In recent years several investigators have initiated trials using reduced -intensity conditioning for patients with a high risk of TRM. In most of these studies TBI is excluded, cytoreductive chemotherapy is given in reduced doses and immunoablative treatment is intensified. We have attempted to reduce the organ toxicity and the cytokine storm by subsituting targeted radiotherapy with a radiolabeled monoclonal antibody for TBI. As monoclonal antibody we used an anti -CD 66 mouse antibody which targets normal granulopoiesis and rapidly localizes to the bone marrow thus producing a powerful crosfire effect. 188 -Re was used as radionuclide because it is a high -energy beta -emitter with just enough gamma -radiation to permit dosimetry. Over the past 2 years we have recruited 12 patients with high -risk haematological malignancies ( 8 acute leukaemias Ͼ 1.CR, 3 CML Ͼ 1.c.P., 1 multiple myeloma). Six patients were Ͼ 55 years old and 6 patients were younger than 55 but had received a prior SCT ( 4 allogeneic, 2 multiple autologous). All patients demonstrated a favourable dosimetry i.e. a higher dose to the marrow or spleen than to any other organ. The median marrow dose was 15 Gy and all patients were subsequently treated with fludarabine 180mg / m2, ATG 40mg / kg plus / minus Melphalan. The graft consisted of T -cell depleted G -CSF mobilized PBPC from an HLA -compatible family ( n = 11) or MUD donor ( n = 1). The acute toxicity of the radiolabeled antibody was minimal, organ toxicity posttransplant was low overall but one patient developed idiopathic pneumonitis ( lung dose 0,07 Gy). All patients engrafted and became full donor chimeras. No primary acute GvHD was observed but one patient developed grade III acute GvHD after a donor lymphocyte transfusion. Three patients with advanced leukaemia have relapsed all of whom had received a prior SCT. Four patients have died of transplant -related complications ( 1 idiopathic IP, 1 P. carnii IP, 2 infections) and 6 patients are currently alive ( 1 in relapse). These preliminary data demonstrate the feasibility of the approach, a longer followup is however required for the evaluation of therapeutic efficacy. Refractory or advanced myeloid leukemias have a poor prognosis Allogeneic stem cell transplantation (alloSCT) is the only therapeutic option which has the potential of inducing long term complete remissions. AlloSCT however is associated with a 30 -40% transplant related mortality (TRM), if conventional, myeloablative conditioning regimens are used. Achieving engraftment with fludarabine-based reduced intensity conditioning regimens may decrease toxicity and improve results. We therefore developed a tandem strategy combining a cytoreductive intensive chemotherapy with upfront reduced intensity S277
Patients over the age of 55 and patients with comorbidity have traditionally been excluded from allogeneic stem cell transplantation (SCT) because of the high transplant -related mortality (TRM) in this group of patients.In recent years several investigators have initiated trials using reduced -intensity conditioning for patients with a high risk of TRM. In most of these studies TBI is excluded, cytoreductive chemotherapy is given in reduced doses and immunoablative treatment is intensified. We have attempted to reduce the organ toxicity and the cytokine storm by subsituting targeted radiotherapy with a radiolabeled monoclonal antibody for TBI. As monoclonal antibody we used an anti -CD 66 mouse antibody which targets normal granulopoiesis and rapidly localizes to the bone marrow thus producing a powerful crosfire effect. 188 -Re was used as radionuclide because it is a high -energy beta -emitter with just enough gamma -radiation to permit dosimetry. Over the past 2 years we have recruited 12 patients with high -risk haematological malignancies ( 8 acute leukaemias Ͼ 1.CR, 3 CML Ͼ 1.c.P., 1 multiple myeloma). Six patients were Ͼ 55 years old and 6 patients were younger than 55 but had received a prior SCT ( 4 allogeneic, 2 multiple autologous). All patients demonstrated a favourable dosimetry i.e. a higher dose to the marrow or spleen than to any other organ. The median marrow dose was 15 Gy and all patients were subsequently treated with fludarabine 180mg / m2, ATG 40mg / kg plus / minus Melphalan. The graft consisted of T -cell depleted G -CSF mobilized PBPC from an HLA -compatible family ( n = 11) or MUD donor ( n = 1). The acute toxicity of the radiolabeled antibody was minimal, organ toxicity posttransplant was low overall but one patient developed idiopathic pneumonitis ( lung dose 0,07 Gy). All patients engrafted and became full donor chimeras. No primary acute GvHD was observed but one patient developed grade III acute GvHD after a donor lymphocyte transfusion. Three patients with advanced leukaemia have relapsed all of whom had received a prior SCT. Four patients have died of transplant -related complications ( 1 idiopathic IP, 1 P. carnii IP, 2 infections) and 6 patients are currently alive ( 1 in relapse). These preliminary data demonstrate the feasibility of the approach, a longer followup is however required for the evaluation of therapeutic efficacy.
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Tandem strategy combining intensive cytoreduction and allogeneic sct with reduced intensity conditioning for high risk myeloid leukemias M. Schleuning, C. Schmid, O. Stö tzer, G. Ledderose, H.-J. Kolb (Mü nchen, D) Refractory or advanced myeloid leukemias have a poor prognosis Allogeneic stem cell transplantation (alloSCT) is the only therapeutic option which has the potential of inducing long term complete remissions. AlloSCT however is associated with a 30 -40% transplant related mortality (TRM), if conventional, myeloablative conditioning regimens are used. Achieving engraftment with fludarabine-based reduced intensity conditioning regimens may decrease toxicity and improve results. We therefore developed a tandem strategy combining a cytoreductive intensive chemotherapy with upfront reduced intensity S277 conditioning for alloSCT. Nineteen patients received fludarabine 4x30mg/m 2 , AraC 4x2g/m 2 , and Amsacrine 4x100mg/m 2 . After a three day pause they received 4Gy TBI followed by Cytoxan 2x40mg/kg or 2x60mg/kg and ATG 3x10mg/kg or 3x20mg/kg, with the higher dose used with unrelated donors. Six patients had secondary AML after MDS, 4 of them with unfavorable karyotypes, one patient had AML in third CR, six patients had primarily or relapsed refractory disease, and five patients had CML in blast crisis. Five patients received grafts from HLA-identical siblings and 14 from matched unrelated donors. Median patient age was 46.7 with a range from 29.6 -61 years. Overall survival was 50% at a median follow-up time of 174 days (range 13 to 363 days). All patients surviving more than 30 days engrafted and all but one patient with CML blast crisis achieved a CR. Compared to a historical control, TRM could be reduced from 38% to 16% at day +100. Three patients relapsed at d +48, d +70 and d +106 respectively. One of these patients refused further treatment and died from leukemia. Another patient was treated with intensive chemotherapy followed by GM-CSF and a second peripheral stem cell transplantation without prior conditioning and achieved again a CR. However, later she developed an extramedullary CNS relapse from which she finally died. The third relapsed patient had an extramedullary relapse in the skin. She was treated identical and developed acute GVHD with the skin nodules regressing. Causes of death were recurrent or persistent leukemia in 3 patients, acute GVHD in one patient and infection in three patients. In summary, treatment with HD-AraC, fludarabine and amsacrine followed by alloSCT with reduced intensity conditioning is safe and has the potential of inducing sustained remissions in high risk myeloid leukemias. We report our experience in allografting 30 patients with lymphoproliferative disease (LPD) with a conditioning regimen combining BEAM with pre-transplant Campath 1G (Day -5 to -1). Fludarabine (30mg/m2 Day -9 to -7) was added in 3 cases. Post-transplant DLI's have been utilised for persisting disease or relapse. 30 patients with median age 47.6yrs (range 18.9-59.5yrs) underwent transplantation for relapsed (n=20) or high-risk LPD using HLA identical (sibing n=25, unrelated n=2) or 1 antigen mismatched sibling donors (n=3). Pre-transplant histology was high-grade NHL(n=7), low-grade NHL(n=7), transformed low-grade NHL(n=5), CLL(n=4), Hodgkin's disease(n=3), mantle cell lymphoma(n=2) and PLL(n=2). Median time from diagnosis to transplant was 1.3yrs with a median of 2 previous lines of chemotherapy (range 1-5). Conditioning employed BEAM-Campath (n=27) or Flu/BEAM-Campath (n=3) with median transplanted CD34 dose of 4.5x10ˆ6/kg. Stem cell source was PBSC(n=24),BM(n=5) and PBSC/BM(n=1). CSA and Methotrexate (10mg/m2 Day+1+3+6) were used for GVHD prophylaxis with CSA withdrawn by 3 mo. 1 patient died at day +12 of progressive lymphoma and 1 patient had primary graft rejection in association with CMV reactivation (requiring further allogeneic PBSC infusion). The remaining patients engrafted with a median of 15 days to both neutrophils Ͼ0.5 and platelets Ͼ20. 1 patient developed autologous reconstitution and has successfully engrafted following a second allograft procedure, 2 patients had secondary graft failure at 1-3 mo and 6 developed mixed chimerism (3 of whom subsequently achieved full donor chimerism following DLI).There have been 3 transplant related deaths (2 viral pneumonitis and 1 Pseudomonas pneumonia) and 6 patients developed Grade I/II acute GVHD post-transplant. Of 28 evaluable patients 18 achieved a CR at 2-3 mo post-BMT and 1 patient in PR at 3 mo subsequently attained CR following DLI therapy resulting in an overall CR rate of 68%. 3 patients had progressive disease and 6 have relapsed (2 of whom have subsequently achieved CR following DLI therapy). OS is 77% and EFS 44% at 3 yrs.18 of 28 evaluable patients (64%) are currently alive and lymphoma-free with a median follow-up of 1.2yrs (range 0.1-3.8yrs). Our data supports the use of this regimen in conditioning for allogeneic transplantation in LPD with a low TRM (10%) & low risk of GVHD. Our results confirm that DLI can induce CR in patients who fail to achieve CR or relapse post-transplant.
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Non-Myeloablative Stem Cell Transplantation (NMSCT) in AML, ALL and MDS: disappointing outcome for patients with advanced phase disease K. Rezvani, M. Lalancette, R. Szydlo, D. Blaise, S. Slavin, P. Alessandrino, M. Michallet, D. Niederwieser, J. Apperley, F. Frassoni (London, UK) 154 patients with ALL, AML and MDS who underwent NMSCT between April 1994 and August 2000 were reported to the EBMT ALWP by 33 centres. 40 patients were transplanted for ALL (21 in CR1 or 2, 19 with relapsed/refractory disease), 69 for AML (27 CR1 or 2, 42 beyond CR2, in partial response, relapsed/refractory disease). 81 patient were males. The median age at transplant was 51 years (3-68). Median time from diagnosis to transplant was 16 months. 131 patients received cells from HLA identical siblings, 17 from matched volunteer unrelated donors and 6 from other donors. 89% of patients undergoing a MUD transplant received a T cell depleted graft (TCD). In the majority the conditioning regimen was based on a combination of fludarabine (127) and other cytotoxics i.e. busulphan or melphalan. The median time to neutrophil engraftment (Ͼ0.5 x109/l) and to platelet engraftment (Ͼ50 x109/l) were 15d (8-60) and 17d (10-84). 11 patients had primary graft failure. 58/134 evaluable patients (43%) developed aGVHD (34 grades 1&2, 24 grades 3&4). 23 patients received DLI. Among 118 patients evaluable for chimerism, 91 (77%) achieved 95% donor chimerism. At 1 year the overall survival (OS), TRM and relapse rates (RR) for all patients were 40%, 33% and 33% respectively. All patients with ALL had a 1 year OS of 15%, TRM 72% and RR 55%. The outcome for patients in CR1&2 was the same as patients in later disease stages. For AML patients the OS, TRM and RR were 41%, 47% and 30% respectively. Patients in CR1&2 had the best outcome with OS, TRM and RR of 67%, 17% and 21% respectively compared to 24%, 68% and 46% in patients with more advanced disease. 3 patients with RA/RARS survived at 1 year without disease progression. Patients with more advanced MDS had 62% OS at 1 year, 48% TRM and 33% RR. There was no significant influence of age, sex, TCD and donor type on OS and TRM. The underlying disease (ALL at any stage and advanced phase AML) was the only factor that influenced survival. In conclusion NMSCT carries a low risk of TRM and encouraging survival at 1 year for selected patient groups. Patients with ALL do not seem to benefit from NMSCT at any disease stage. For patients with advanced phase disease the TRM approaches that of conventional transplants and NMSCT does not appear to confer an advantage. Only 23 patients received DLI and more judicious use of pre-emptive therapy may help overcome the high relapse rates. Transplant related mortality remains a major problem in older patients undergoing allogeneic hemopoietic stem cell transplantaion. As an alternative strategy, more recently less toxic, lower dose non-myeloablative (NMA) regimens have been used, aiming at exploiting the graft versus leukaemia effect. We have analysed data from the Chronic Leukaemia Working Party of the EBMT, were 58 patients with CML (CP1=32, CP2=6, AP=4, BC=12, unknown=4) have undergone NMSCT in 20 centres between April 1997 and June 2000. 30 patients were males and the median age at transplantation was 51.5 years (29-65). Median time from diagnosis to transplant was 19 months (3-173). Median follow-up post transplant is 9.7 months. 45 patients were transplanted from HLA identical siblings, 11 from MUD, and 2 from other donors. The majority of patients (54) were conditioned with fludarabine based chemotherapy regimens, 37 with additional busulfan. Serotherapy with ATG/ALG was given to 40 patients and 3 additional patients received in vivo T cell depletion with Campath 1H. The majority (12/13) of unrelated grafts were T Cell depleted using ATG/ALG (10) or Campath 1H (2). 54 patients received cyclosporin. The source of stem cells was BM for 21 patients, PBSC in 36, and 1 patients received both. 4 patients did not engraft. The median time to neutrophil engraftment (Ͼ 0.5 X 10 exp9/L) was 15 days (0-76) and to platelet engraftment (Ͼ 50 X 10 exp9/L) was 17 days (0-81). 13 of 53 evaluable patients patients (24%) developed grade II-IV acute GVHD, and 17/38 chronic GVHD. Grade III-IV acute GVHD was seen in 7 of 41 (17 %) patients transplanted using HLA identical siblings, and in 0/11 patients grafted from unrelated donors. 12 patients received DLI. Data relating to chimerism were available from 50 evaluable patients. 39 patients (78 %) achieved Ͼ95 % donor chimerism. At 15 months the overall survival (OS) and transplant related mortality (TRM) were 72% and 23.3%. There was no significant influence of sex, interval between diagnosis and transplant, T depletion and type of donor on OS and TRM. Age and status at the time of transplant were the factors that influenced one year survival (OS): patients aged less than 55 years had a 84% one year OS, patients older than 55 years had a 53% one year OS (p=0.06). The one year OS was 87 % and 58% for the CP-1 and more advanced phase ( p=0.07) respectively. The LFS was 75 % and 46 % (CP-1 and others respectively, p= 0.18). NMSCT offers a potential alternative to conventional allogenic bone marrow transplantation in patients with CML. Randomized studies are needed to assess the efficacy of this procedure in comparison to conventional allogeneic BMT. In a retrospective study of the EBMT, data were collected from 54 patients who received NMSCT for myeloma in 20 member centres between November 1997 and April 2000. The median age was 48 years (range 33-62) and 35 were male. 29 patients were transplanted in first (14) or subsequent (15) PR, one in CR, and 18 with refractory or progressive disease. 45 patients received cells from HLA identical siblings, and 6 from matched unrelated donors. 40 patients were grafted with PBSC, 10 with BM, and one patient received both PBSC and BM. The preparative regimen contained fludarabine in 50 transplants, of which 29 received additional melphalan and 19 busulfan. All except one patient received cyclosporin, 26 were given ATG/ALG, and 17 were depleted of T cells in vivo using Campath 1H. There was one graft failure. The median time to neutrophil engraftment (Ͼ 0.5 X 10 exp9/L) was 12 days (range 0-25) and to platelet engraftment (Ͼ 50 X 10 exp9/L) was 15 days (range 1-63). GVHD Grade II-IV developed in 28% of patients. Data on chimerism were evaluated in 33 patients and 22 achieved Ͼ95% donor engraftment. Best response to NMSCT was new CR in 18, continous CR in one, new PR in 6, and continous PR in15. 5 patients were refractory to treatment and 8 are not evaluable (either because of early mortality or short follow-up). 12 patients received donor lymphocyte infusions ( 5 in CR, 4 in PR, 3 refractory) and 2 achieved CR after this treatment, which has been sustained to date. TRM at one year for the entire group was 41%. The relapse incidence at one year was 14%. Actuarial overall survivals (OS) at one and two years were 52 and 44% respectively. The one year OS, TRM, and relapse rate for the good risk group (CR, PR1, PR2) were 83%, 13%, and 11% respectively, compared to 25%, 68%, and 20% for poor risk patients. Surprisingly, the outcome of patients transplanted in PR2 was similar (83% OS) to that for patients in CR or PR1 (79% OS). In conclusion, NMSCT offers a potential alternative to conventional allograft for patients with responsive disease. TRM was low and one year survival was good for patients in CR or PR. Longer follow-up will be required to estimate the effects on disease free survival. DLI can improve the response rate and should be part of an integral approach to NMSCT.
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GVHD is essential for response in allogeneic minitransplants: comparison of T-cell depleted and non-T-depleted strategies
We compared a pilot protocol (Basel protocol) of reduced intensity conditioning, T-cell depletion and high stem cell dose (Ͼ 10x10E6 CD34/kg) with a minitransplant protocol without T-cell depletion, Fludarabine + TBI (2Gy) conditioning and GvHD prophylaxis with cyclosporine + mycophenolate (Seattle protocol). Incremental doses of donor lymphocyte infusions (DLI) were given for mixed chimerism in the absence of GvHD. In the Basel protocol, T-cell depletion was to Ͻ1.0x 10E5 lymphocytes/kg using CD34 selection and CD4/8 depletion (Isolex 300i) steps. Conditioning was with cyclophosphamide 200 mg/kg and ATG. Mainly donor availability determined whether patients were selected for the Basel (n=10) or the Seattle (n=9) protocol. Median age was 53 (36-62) years. All patients were at high risk for transplant-related complications with a standard transplant and had AML (2), CML (4), CLL/NHL (4), MDS/MPS (4), MM (5). All had advanced disease. Median follow-up is 10 (2-24) months. Donors were HLA-identical siblings (Basel:9; Seattle:5) or mismatched related or matched unrelated donors (Basel:1; Seattle:4). The median CD34 dose (10E6/kg) was 12.0 (9.8-20.2) in the Basel and 7.3 (2.2-10.6) in the Seattle protocol (p=0.001). Time to neutrophil recovery was 13.5 (10-20) days, achieved in all patients on the Basel protocol; but by day 30, 2 patients had lost their graft and 4 additional patients later rejected the graft in spite of DLI. In patients on the Seattle protocol time to neutrophil recovery was 25 to 40 days in 3 patients, 6 patients did not experience aplasia. 3 patients on the Seattle protocol had primary or secondary graft failure. 8 patients on the Basel protocol and 1 patient in the Seattle protocol went on to receive incremental dose DLI. Grade II-IV acute GvHD was observed in 3/10 patients on the Basel protocol and 7/9 on the Seattle protocol (pϽ0.04). Of the 10 patients on the Basel protocol 5 had a response, stable in 4. Of the 5 nonresponders 4 received a second transplant using the Seattle protocol. 2 of them are alive in CR, 1 is alive with disease, 1 died of infectious complications. Of the 9 patients treated on the Seattle protocol 5 responded initially, 2 of whom relapsed, 3 are alive with disease, and 1 rejected and died of progressive disease. Response was strongly associated with GvHD. All patients achieving complete chimerism with both protocols had grade II-IV acute GvHD, as had 7 of 8 patients achieving a complete remission. T-cell depleted minitransplants, despite high stem cell dose and DLI are associated with more graft failure, less acute GvHD as compared to non-T-depleted minitransplants.
P702 Predictive model to assess the risk of Treatment Related Mortality (TRM) in patients undergoing Allogeneic Hematopoetic Stem Cell Transplant (AHSCT)
S. Kulkarni, R. Powles, B. Sirohi, C. Horton, R. Saso, J. Mehta, S. Singhal, J. Treleaven (Sutton, UK)
The prospectively maintained database at this hospital identified 968 patients (M:574,F:394, median age:26yr. range:1-56) who received allograft were analysed with the aim of designing a prognostic model to predict treatment related mortality (TRM) based on the physiological parameters before the start of conditioning treatment. Transplants were done for Ac.Leukaemia (AL,n=680), CML (n=141) or other malignancies (n=147) using either TBI (n=799) or non-TBI (n=169) conditioning and CyA (n=519), CyA+Mtx (n=400) or other GVHD prophylaxis (n=49). Donor was HLA-identical sibling (n=826), MUD (n=94) or mismatched family member (n=48). 514 had good risk and 454 had poor risk disease at the time of allograft. Source of stem cell was marrow (n=905) or PBSC (n=63). For each patient in addition to demgraphic features, the maximum level of bilirubin, ALT, ALP, urea, creatinine, serum albumin, haemoglobin, WBC, platelet and EDTA levels within 15 days of starting conditioning was identified and used for analysis. The 3yr OS was 40% (SE+2% ) and TRM was 43%(SE+1.7 ). In univariate analysis, TRM was significantly low for age Ͻ26 (p=0.001), good risk disease (p=0.0045), albumin Ͼ39g/L (p=0.0092), creatinine Ͻ80 (p=0.09), sibling donor (p=0.0027), GFR Ͼ107ml/min (p=0.054), urea Ͻ 4mmol/l (p=0.008) and HbϾ11.3 gm/dl (p=0.011). Multi-variate analysis identified early stage disease (RR:0.73, 95% CI:0.58-0.92;p=0.007), age below 26 (RR:0.78, 95% CI:0.61-0.99;p=0.042), albumin above 39g/l (RR:0.64, 95% CI:0.52-0.81;p=0.0001) and creatinine below 80mmol/l (RR:0.73, 95% CI:0.57-0.94;p=0.015) as independent predictors. These four risk factors (RF) were used to divided the patients in 5 groups (no RF to 4 RF) and estimation of TRM in these groups showed that patients with 0-1 risk factors had 35% risk, those with 2 risk factors had 45% risk and those with 3-4 factors had 58% risk of TRM at 1 yr. (p=0.00001). In conclusion, routine physiological and demographic parameters help to define the risk of TRM in allograft population. This model will help to devise risk based conditioning regimen and identify patients suitable for non-myeloablative allogeneic transplants.
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Mixed chimerism is common at the time of acute GVHD and disease response in patients receiving non-myeloablative conditioning and allogeneic SCT J. Mattsson, M. Uzunel, M. Brune, L. Barkholt, U. Stierner, P. Heuntschke, J. Aschan, O. Ringden (Huddinge, Gö teborg, S)
We report clinical outcome and results of chimerism analysis in different cell lineages in 30 patients given a non-myeloablative conditioning followed by allogeneic SCT. Diagnoses were: CML (n=11), renal cell carcinoma (RCC) (n=8), colon cancer (n=3), AML (n=3), MDS (n=2), multiple myeloma (n=1), B-CLL (n=1) and Fanconi anemia (n=1). Twenty-one patients received SCT from HLA-identical siblings and 9 patients received SCT from matched unrelated donors. Median age was 53 (28-77) years. Conditioning regimens were fludarabine (30mg/m2x 5-6), busulfan (4mg/kg x 2) or TBI (2Gy), and ATG. Twenty-nine patients received PBSCT and one patient received a BMT. GVHD prophylaxis consisted of CsA+MTX (n=10), CsA+MMF (n=11) or CsA alone (n=9). All patients were analysed with PCR of VNTRs on day 14, 21, 28 and every second week up to 3 months and monthly thereafter. All samples were cell-separated for T-, B-and myeloid-cells by using immunomagnetic beads. Nineteen patients are alive with a median follow-up of 10 (4-18) months. All patients in this study engrafted. Two out of 8 patients with Ͼ50% recipient T-cells on day +28 after SCT experienced a graft failure or rejection as compared to 0/22 with Ͻ 50% recipient Tcells (p=0.06). Acute GVHD occurred in 22 patients; 7 grade I, 11 grade II and 4 with grade III/IV. Two patients died due to aGVHD in this study. Eighteen of the 22 patients with aGVHD were mixed chimeric in the T-cell fraction at the time of aGVHD. However, all patients with aGVHD became donor chimeras in the T-cell fraction vs. 3/8 patients without aGVHD (pϽ0.001). Donor chimerism (DC) was established in 83% of the patients in the T-and myeloid-cell fraction. Median time for DC to occur was 90 (20-461) and 46 (14-461) days for T-and myeloid-cells, respectively. Disease response (DR) was diagnosed in 15 patients median 100 (37-531) days after SCT. Nine patients with CML (RT-PCR negative), 2 AML, 1 MDS, 2 RCC and 1 patient with colon cancer showed DR. At the time of DR, 6/15 patients were mixed chimeric in the T-cell fraction. CsA discontinuation and DLI had little effect on DR, only 2 patients showed DR after immune modulation in this study.
In conclusion, mixed chimerism in the T-cell fraction is common at the time of aGVHD and DR in patients conditioned with nonmyeloablative therapy. However, aGVHD is important for establishment of DC.
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Nonmyeloablative T-cell depleted stem cell transplantation for severe aplastic anaemia: low incidence of take failure, little graft verus host disease and favourable outcome N.P.M. Schaap, A.V.M.B. Schattenberg, F. Preijers, R. van der Maazen, T.J.M. de Witte (Nijmegen, NL) Fourteen patients (pts) (8 males and 6 females) with severe aplastic anaemia (SAA) were transplanted with grafts depleted of lymphocytes by counterflow centrifugation. Median age of the pts was 30 (range, 17-53) years. Immunosuppressive treatment before stem cell transplantation (SCT) consisted of cyclosporine A (CSA) and anabolic steroids in 7 pts. Three pts were treated with CSA, anabolics and ATG, two pts received CSA only, one patient was given corticosteroids combined with anabolics and followed by ATG and one patient did not receive any treatment at all, respectively. The median number of red cell and platelet transfusions before SCT was 28 (range, 6-90) and 16 (range 0-86), respectively. Donors were HLA-identical siblings in 11/14 pts. One patient was transplanted with a one locus mismatched sibling and two pts received bone marrow from a voluntary unrelated donor. Median time from diagnosis to SCT was 8 (range 3-14) months. All pts were conditioned with 6 x 2 Gy total lymphoid irradiation in a dose rate of 80 cGy/min divided over three consecutive days followed by cyclophosphamide 50 mg/kg body weight on 4 consecutive days. The median number of T-lymphocytes in the grafts was 0.7 (range, 0.4-1.9) x 10E6 CD3+ cells/kg body weight. Normal engraftment was observed in 13/14 pts. Only one patient had an early rejection of the bone marrow. This patient died of infection. Post transplant immunosuppression consisted of CSA gradually tapered in three months. After SCT ten pts developed acute GVHD Ͻ grade 2 without any chronic GVHD. Two pts had grade 2 acute GVHD with progression to limited chronic GVHD. Another 2 pts developed grade 3 acute GVHD and both died early after SCT (TTP, suicide). Chimerism post SCT was evaluated using red cell phenotyping and/or cytogenetics. Eight out of ten pts alive developed complete donor chimerism in median 6 (range, 3-36) months after SCT. In two pts with normal blood counts an increasing number autologous cells was observed. Four pts died Ͻ 3 months after SCT. The median follow-up of the pts alive is 97 (range, 54-174) months. The eight-year probability of event free survival is 64% (95% CI 56-72%). Five pts died after SCT (TTP n=1, meningococcal sepsis n=1, pulmonary embolism n=1, suicide n=1 and rejection n=1). We conclude that in pts with SAA, non myeloablative allogeneic SCT with T-cell depleted grafts results in a low incidence of take failure, little GVHD and favourable outcome.
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Significant GVHD-related mortality after reduced intensity conditioning and allogeneic stem cell transplantation in high risk patients J. Schetelig, N. Krö ger, T.K. Held, A. Krusch, T. Zabelina, M. Dubiel, C. Thiede, G. Ehninger, A. Zander, W. Siegert (Berlin, Hamburg, Dresden, D) Purpose: To study incidence and causes of treatment related mortality (TRM) in a group of high risk patients (pts) after reduced intensity conditioning and allogeneic stem cell transplantation (HSCT). Patients and methods: We report on 50 pts with a minimum follow up of 100 days. Risk factors for adverse transplantation outcome were: age Ͼ50 in 24/50 pts, relapse after high-dose therapy in 18/50 pts, history of fungal or chronic bacterial infection in 18/50 pts and relevant medical syndromes in 24/50 pts. 44 pts suffered from advanced hematologic malignancies and 6 had chemotherapy-refractory solid tumors. All patients received fludarabine, busulfan and ATG (Slavin, 1998) as conditioning regimen. GVHD-prophylaxis was carried out with ciclosporine (CSA) alone or CSA combined with "short course" methotrexate or mycophenolate mofetil. Donors were HLA-identical siblings (n=23), non-HLA-identical family members (n=7), matched unrelated donors (n=17) and unrelated donors with one minor mismatch (n=3). TRM was defined as any cause of death other than tumor progression.
Results: After a median follow-up of 12 months 23 pts are alive, 27 pts died. TRM was 13/50 (26%). Death was directly or indirectly related to chronic GVHD in 10 pts, including chronic obstructive lung disease (n=2), intracranial bleeding due to ITP (n=2) and infectious complications: bacterial or fungal sepsis (n=5), toxoplasmosis (n=1). Median time to GVHD-related-death was 7 months from transplantation. Incidence of acute GVHD grade II/III/IV (n=15/4/2) was 42%. Chronic GvHD occurred as limited (n=12) or extensive (n=12) disease in 56% of pts who reached day +100. Treatment related deaths which were not caused by GVHD occurred in 3 pts: HITII and myocardial infarction d+9, fungal sepsis d+11 and transplant failure after CMV-reactivation d+90. Conclusions: We observed significant GVHD-related mortality in the posttransplant period. However, even in high risk patients TRM not caused by GVHD was a relatively rare event. Encouraged by the early reports of low regimen-related toxicity and prompt engraftment, οmini-allografts' using nonmyeloablative doses of cytotoxic agents together with varying combinations of immunosuppressive agents are being increasingly used for treating malignant and non-malignant conditions. However the impact of such immunosuppressive protocols on viral infections and immune reconstitution has not been reported. We prospectively studied the incidence of viral infections, EBV-specific immune response and T-cell subset recovery in 14 patients receiving a non-myeloablative (NMT) conditioning (fludarabine, Campath-1H and melphalan). This was compared with 14 age-matched patients conditioned with conventional myeloablative regimens (CMT) receiving T-cell depleted grafts (with Campath-1H in vitro). There was no difference in the neutrophil engraftment (CMT 13.5 days vs NMT 16 days) and incidence of GVHD Ͼ2 (NMT 3 vs CMT 1) between the groups. At least one virus infection was detected in 13/14 NMT patients (CMV 8/9 at risk, adeno 7, polyoma 6, respiratory viruses 5, HSV 3, HZV 4), compared to 7/14 in the CMT group (CMV 3/6 at risk, adeno 2, polyoma 1, respiratory viruses 1, HSV 3, HZV 3); p=0.02, OR=13 . More NMT patients had multiple infections (8 vs 3 in CMT group) with a much earlier onset of infection (median 24 days (15-250) vs 60 days(15-120) in NMT group); p=0.02. Viral disease was documented more frequently in NMT patients (8 vs 4 in CMT group) and so were viral deaths (3 vs 0). EBV load was low in both groups with no occurrence of EBV-LPD. The median time to first EBV-specific T cell response was 8 months for NMT patients , compared to 3.2 months for CMT patients (p=0.03). CD3, 4 and 8 recovery were delayed in both groups, but time to achieve a CD4 count of 200/ mm was more delayed in the NMT group (median 12 months vs 7 months for CMT, p=0.03). Thus, despite prompt engraftment and a low incidence of GVHD, non-myeloablative conditioning was associated with prolonged immune-paresis, resulting in significant morbidity as well as mortality (20%) associated with viral infections. The effect of various NMT protocols on immune reconstitution and viral infections needs to be reviewed, before recommending its widespread application. The aim of this retrospective study was to investigate whether a dose-reduction of the TT-CTX based preparative regimen might have a beneficial effect on the outcome following stem cell transplantation. Patients/Methods: Between January 1994 and September 2000, 176 patients with hematological malignancies underwent an HLA-identical sibling donor transplant after receiving a reduced intensity conditioning including THIO 10 mg/Kg and CY 100 mg/Kg (THIO10-CY100, n=44) or a conventional preparative regimen which included THIO 15 mg/Kg and CY 120-150 mg/Kg (THIO15-CY150, n=132). Bone marrow (BM) was the source of stem cells in 22 (50%) cases of the THIO10-CY100 group and 50 (38%) cases of the THIO15-CY150 group, whereas PBSC were used in 22 (50%) and 82 (62%) cases of the two groups respectively. 41% (18/44) of the patients in the reduced intensity group had advanced disease as compared to 66% (87/132) in the conventional group (p=0.006). Patients with advanced disease were almost equally distributed in the two groups among BM and PBSC recipients. The median age was 52 (range 34-65) and 45 years (range 18-59) in the two groups respectively (pϽ0.0001). GVHD prophylaxis included cyclosporine (CyA) and MTX (n=171), CyA alone (n=3) or CyA+other (n=2). Results: Acute GVHD grade II-IV was observed in 43 % of the THIO10-CY100 recipients and 40% of the THIO15-CY150 recipients (p=0.8); 4 out of 40 (10%) THIO10-CY100 recipients vs 20 out of 101 (20%) THIO15-CY150 recipients developed extensive chronic GVHD (p=0.2). The relative risk of TRM with the THIO10-CY100 regimen was not significantly different from the risk with the THIO15-CY150 regimen in patients with early disease (20% vs 13%, p=0.9) or advanced disease (22% vs 32%, p=0.2). Among patients receiving conventional regimens, there was a nonsignificant trend toward a reduced TRM for BM recipients as compared to PBSC recipients (14% vs 36%, p= 0.06); the corresponding figures for patients receiving the reduced intensity regimen were, respectively, 12% vs 31% (p=0.2). With a median follow-up of 36 (2-69) months in the THIO10-CY100 group and 33 (3-77) months in the THIO15-CY150 group, the OS rate was 61% and 44% respectively (p=0.004). Conclusion: these preliminary results suggest that TRM might be influenced by the source of stem cells especially with conventional preparative regimens and by the intensity of the conditioning when the transplant procedure is extended to an older patient population. Allogeneic HSCTs for patients with AML are usually limited to patients below 40-55 years because of the high risk of transplantrelated mortality (TRM). A safe approach at allografting that uses 2 Gy TBI before and a combination of MMF and CSP after transplant has been applied to patients with hematological malignancies with HLA-identical and matched unrelated donors. In order to decrease the risk of rejection, fludarabine (FLU), 3x30 mg/sqm was added to the regimen. Here, we report on 25 patients (pts.) with AML (CR=18, PR=2,relapse=3, induction failure=2)given HSCT from related (n=16) and unrelated donors (n=9, 2 pts. with 1-Ag-mm). Pts. were 36-71 years old (median 59 years). Follow-up ranges from 38 to 842 days (median 214 days). Donor engraftment on day 28 for related HSCT was: (range/median/) blood T cells (20-87/52,5/%) and by day 56 (1,3-95/64,2/%). Donor engraftment for unrelated HSCT was: blood T cells on day 28 (75-100/100/%) and by day 56 (65-100/100/%). Two pts. rejected after related HSCT, no pt. after unrelated HSCT. GvHD occured in 5 pts. after related and in 8 pts. after unrelated HSCT; it was fatal in 1 pt. with liver GvHD which occured 150 days after unrelated HSCT. One pt. died after related HSCT of mucormycosis and pneumonia, after unrelated HSCT one pt. died of refractory gastrointestinal bleeding, one further of sudden cardiac death 4 months after transplant (TRM 16%). After related HSCT, 9/16 pts. are alive, 6 pts. died of relapse. Nine pts. are in CR, one died of TRM. After unrelated HSCT, 6/9 pts. are alive in CR, 2 died of relapse. We conclude that related and unrelated HSCT with minimal conditioning is a feaseable and safe strategy for older pts. with AML. The unrelated HSCT was extremely effective in AML pts. despite high tumor load (3 relapses, 1 PR, 2 CR-3, 1 CNS relapse) at time of HSCT. A phase II study of the Eastern Germany Study Group (OSHO) has been started in pts. Ͼ 55 years in Ͼ 1.CR who have a sibling donor. It is not known whether reduced conditioning is associated with prolonged period of detectable disease after SCT in patients with CML. We have therefore compared bcr-abl transcript levels in patients receiving a conventional conditioning with those receiving reduced conditioning. We also made chimerism studies in both patient groups. RT-PCR analysis was performed for detection of the bcr-abl translocation product. For quantification a competitive-PCR analysis was done. Chimerism status of T-cells and granulocytes was studied with VNTR-PCR. Myeloablative (MYA) conditioning: Nine patients, 7 MUD and 2 Sib. Median age was 44 (31-53). Conditioning with TBI+Cy (n=4) or Bu+Cy (n=5). All seven MUD patients were also given anti T-cell antibodies. GVHD prophylaxis consisted of CsA+MTX for 8 patients and CsA+ MMF for one patient. One patient died of GVHD 7 months post-SCT. Median follow-up time: 15 months (6-21). Nonmyeloablative (NYA) conditioning: Eleven patients, 2 MUD and 9 Sib. Median age was 53 (40-63). Conditioning with Flu+Bu+anti T-cell antibodies. GVHD prophylaxis: CsA+MTX (n=7) or CsA alone (n=4). One patient died of GVHD 5 months post-SCT. Median follow-up time: 10 months (7-19). Results: At 3 months 2/9 patients were RT-PCR positive for bcr-abl in the patient group receiving a MYA conditioning compared to 7 out of 11 patients in the NYA patient group. The bcr-abl/abl ratio was in general one log higher in patients with NYA conditioning compared to MYA patients during the first 3 months. In the last follow-up sample 3/9 patients were RT-PCR positive in the MYA group (2 patients were initially RT-negative but have become RT-positive at low levels, 1 patient has relapsed). In the NYA group 2/11 patients are still bcr-abl positive, both have relapsed. In patients with MYA conditioning T-cell mixed chimerism was found in 4 patients. Three were only mixed the first month while one patient that eventually relapsed was mixed the whole post-transplant period. All patients with NYA conditioning were T-cell chimera with a median time of 97 days (28-365). Of the bcr-abl negative patients, 3/9 patients were still T-cell chimera at the time they became bcr-abl negative. Conclusion: Nonmyeloablative transplantation for CML patients seems to work as well as myeloablative transplantation for eradication of residual disease post-SCT. Despite higher bcr-abl levels during the early post-transplant period most patients eventually become RT-PCR negative for bcr-abl.
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High proportion of molecular remissions after reduced intensity conditioning and allografting in CML M. Brune, H. Wadenvik, M. Uzunel, J. Mattsson, U-H Mellqvist (Gö teborg, Huddinge, S)
We report clinical outcome and molecular remissions in eight consecutive CML pts, all allografted at Sahlgrenska University Hospital after reduced intensity conditioning. Patients and methods. Four men and 4 women with CML (7 CP1, 1 CP3), age 48 (37-64) yrs. Reduced conditioning was applied because of age or concurrent disease (n=2), or after pts informed choice (n=6). Conditioning regimen was fludarabine 150-180 mg/sqm, busulfan 8 mg/kg and ATG 20-40 mg/kg (Slavin et al 1998) . Pts received PBSC (n=7) or BM (n=1) from HLA-matched siblings (n=5) or unrelated donors (URD; n=3). GvHD propylaxis was CSA alone (n=4) or CSA/Mtx. Median follow-up is 7.5 (1-17) mo as of Nov 8 2000. Toxicity from the regimen was mild. Median time in hospital was 29 (13-46) days. Days with fever was 0.5 (0-3). Numbers of RBC and platelet transfusions during hospital stay were 5 (0-8) and 1.5 (0-4), respectively. Acute GvHD grade 1-2 was seen in 5/8 pts. Limited chronic GvHD was seen in 5/6 evaluable pts. Hemolytic complications. In 2 pts transplanted across major AB0-incompatibilities (recipients 0, donors A) and with long-standing mixed cimerism, high titres (Ͼ=1:256)of anti-donor isoagglutinins, very low reticulocyte counts and RPC transfusion need persisted until 6 mo post-Tx. After achieving complete chimerism, a dramatic increase of reticulocytes and a concurrent decrease in isoagglutinin titers followed by an increase of hemoglobine were observed in both pts. Results. Six out of 7 pts with follow-up Ͼ6 wks are complete chimeras (analyzed by PCR on variable nucleoptide tandem repeat; VNTR), and RT-PCR negative for the bcr-abl fusion gene. Median time to RT-PCR negativity was 97 (28-174) days. The remaining pt -transplanted with BM from an URD -is in hematological remission after 7 mo but still RT-PCR positive and a mixed chimera (T-and B-cells 100% donor, myeloid cells 5% recipient). Conclusion: These early data suggest that reduced intensity conditioning followed by allografting is a safe and feasible procedure in CML with a high proportion of molecular remissions.
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Engraftment kinetics after transplantation of highly purified peripheral blood CD34+ cells with nonmyeloablative conditioning C. Peters, S. Matthes-Martin, G. Fritsch, W. Holter, T. Lion, P. Hö cker, H. Gadner (Vienna, AT) Background: SCT from HLA-identical donors after non-myeloablative chemotherapy is sufficient to establish mixed or complete chimerism and to induce GvL effect in some haematologic malignancies, as well as to correct inborn errors. It was our aim to establish donor hematopoiesis from HLA different related or identical unrelated donors in pediatric patients at high risk for transplant related toxicity or infections, respectively, and to monitor chimerism on FACS-sorted cell lines. Patients and Methods: Twenty seven stem cell transplantations in 21 paediatric patients from alternative donors without myeloablative conditioning regimen are reported. Underlying diseases were haematologic malignancies (n=9), severe combined immunodeficiency (SCID) (n=7), Wiskot-Aldrich-Syndrome (n=1), globoidcell-leucodystrophy (n=1), mucopolysaccharidosis I (n=2), Langerhans-cell histiocytosis (n=1). Donors were haploidentical family donors (FD) in 10 transplantations and matched unrelated donors (MUD) in17 cases. Three different conditioning modalities have been applied: 1) TBI 2 Gy, 2) non-myeloablative chemoconditioning with busulfan and fludarabine or cyclophosphamide and 3) ATG only for patients with SCID, respectively. Tcell depletion was performed by CD34 positive selection (Baxter isolex decive). Blood samples were analyzed daily between infusion of the transplant and hematopoietic reconstitution, using a 3-or 4-color flow cytometric (FACS) approach to quantify circulating leukocytes in PB of myeloablated patients (Ͻ 100 NC/µl). Results: The detection threshold for NC was 1 cell per µl blood. Between days +5 and +16, the onset of hematopoietic reconstitution was detectable in multi-parameter evaluation of the FACS-data. This was a median of 3,5 days before NC increased above 200/µl blood. Molecular engraftment detected by highly polymorphic microsatellite loci (STR-PCR) of FACSsorted NC preceded haematatologic engraftment by a median of 7 days (range, 1-17 days). Primary complete or mixed chimerism could be established in 19 cases. Five non-SCID patients rejected the graft 12 -56 days after allogeneic SCT and 2 SCID-patient (NK+) had no engraftment. All pts underwent second SCT and 5 showed stable engraftment. Conclusion: We conclude that close monitoring of recipient and donor haematopoiesis of FACS-sorted NC by STR-PCR is a highly sensitive method for confirmation of regular haematologic engraftment, rejection or graft failure. It might be extremely important after T-cell depleted stem cell transplantation in order to put through early therapy modifications.
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Profile of peripheral blood lymphocytes in patients receiving nonmyeloablative conditioning of HSCT D. Dlubek, A. Lange (Wroclaw, PL) Recently, conditioning regimens based rather on imunosuppression but not myeloablation (Slavin et al. 1998 ) was introduced. In the present study we analysed whether highly immunosuppressive regimen influences the profile of lymphocytes appearing 2 to 4 weeks after transplantation. Profile of lymphocytes in patients receiving myeloablative (Busulfan, Cyclophosphamide + VP-16 or Thio-tepa) conditioning and in those on HI (Fludarabine 30 mg/m2 for 6 or 5 days, ATG 10 mg/kg b.w. for 4 days and Busulfan 4 mg/kg b.w. for 2 days or Melphalan 140 mg/m2) conditioning was analysed. We found: (i) number of lymphocytes did not differ in patients receiving myeloablative conditioning (MC) vs immunosupressive conditioning (IC) at 21 days post transplant (mean + SEM: 395 cells/ul + 35 vs 459 cells/ul + 134); (ii) patients on IC had lower percentage of CD45RO+ cells in comparison with patients on a MC (38.1% + 5.7 vs 51.2% + 2.9, p=0.01) and it was associated with lower proportion of CD4+ cells (9.7% + 1.4 vs 32.8% + 2.0, p=0.000005); (iii) proportion of CD57+ cells was higher in patients receiving IC (29.5% + 4.5 vs 16.9% + 1.3, p=0.004) and this early increase of CD57+ cells was associated with a higher proportion of CD8+ cells (36.5% +5.8 vs 22.1% + 1.7, p=0.02) and CD56+ cells (37.4% + 5.7 vs 20.0% + 2.1, p=0.007). It appears that immunological reconstitution in patients receiving IC was associated with a lower percentage of helper (CD4+) and memory cells (CD45RO+), on the other hand there was a higher proportion of cytotoxic cells (CD56+) and CD57+ cells (favour post transplant tolerance) as compared to patients receiving MC. The high dose chemotherapy and radiation used as preparative regimen for allogeneic SCT produces considerable morbidity and mortality. An alternative strategy is to use nonmyeloablative conditioning regimens to provide sufficient immunosuppression to allow hematopoietic engraftment and induce subsequent development of a graft versus malignancy effect. We present our data in 17 pts with advanced hematologic malignancies who were not candidates for conventional allogeneic SCT because of older age or poor performance status. All pts had an HLA-matched related donor; 15 received G-CSF mobilized PBSC, 1 BM and 1 BM + PBSC. The median age was 56 years (range 30-66) and there were: 5 NHL, 5 MM, 2 CML (1AP, 1BP), 3 MDS, 1 ALL and 1 HD. At transplant, 1 pt was in 2nd and 1 in 3rd CR, 8 in PR and 7 with resistant disease. The conditioning regimens consisted of Fludarabine at 30 mg/m2 x 3 days (16 pts) associated with either Thiotepa at 5 mg/kg x 2 days (12 pts), or CTX at 300 mg/m2 x 3 days (2 pts), or Melphalan at 100 mg/m2 (2 pts); 1 patient received CTX (300 mg/m2 x 3 days) + Thiotepa (5 mg/kg x 2 days). As GVHD prophylaxis, 11 pts received CSA alone, 5 CSA plus short course MTX and 1 no prophylaxis. Two pts were not evaluable for engraftment because of early death due to infection. The median time to reach a neutrophil count (ANC) of 0.5x109/L and a platelet count of 20x109/L was 15 (range 11 -23) and 17 days (range 10 -27), respectively; in two pts the ANC did not fall below 1 x 109/L. On day 30, chimerism analysis of bone marrow indicated a donor cells between 80% and 100% in all evaluable pts; between day 60 and 90, 4 pts lost the donor hematopoiesis, 2 pts died in CR and 9 continue to have Ͼ90% donor cells. Two pts developed aGVHD gradeϾII. Severe cGVHD occurred in 3 cases and 1 patient showed limited cGVHD. TRM was 33%: 6 pts died from severe infections (2 before the hematopoietic recovery and 4 between day 45 and 180), in one case associated with severe cGVHD. One additional patient died in CR from a brain vascular accident on day 56. Five pts are alive and in CR after a median follow up of 30 months (range 11-43). Five pts relapsed: 4 died from disease recurrence and 1 is in CR after further treatment. Our data confirm that nonmyeloablative allogeneic SCT may provide good results in terms of engraftment and graft vs malignancy effect (RR 33%) in pts with high risk hematologic malignancies, not eligible for conventional allogeneic transplantation.
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Enhanced graft versus tumor effect following minitransplantation (allo-SCT) for refractory lymphoid malignancies (LM) after high dose therapy M. Mohty, N. Fegueux, C. Exbrayat, Zy Lu, E. Legouffe, P. Quittet, E. Lopez-Martinez, P. Latry, B. Klein, Jf Eliaou, Jf Rossi (Montpellier Cedex, F)
Nonmyeloablative conditioning regimens recently proved to allow engraftment of allo-SC with minimal procedure-related toxicity in patients with advanced diseases. Furthermore, allo-SCT is an effective treatment for patients with LM. We present here our data in 11 patients with advanced and previously autografted LM receiving allo-SCT from HLA identical siblings. These results confirm feasibility of this reduced nonmyeloablative conditioning regimen. All patients engrafted. A high response rate could be achieved in this group of refractory and heavily pretreated patients. GVHD and infections are the major cause of treatment failure. Further studies are needed to explore this powerful graft versus tumor effect in less advanced patients. 
